Editas Medicine Announced A Two-year Extension To The Alpha-Beta T Cell Collaboration With Bristol Myers Squibb; The Extension Also Has Options To Extend The Collaboration For Up To An Additional Two Years

Author: Benzinga Newsdesk | May 01, 2024 08:09am

Under the collaboration, Bristol Myers Squibb has opted into 13 different programs across 11 gene targets to date. Two programs are currently in IND-enabling studies, and four programs are in late-stage discovery.

 

Under the terms of the original agreement, Editas Medicine may develop genome editing tools and Bristol Myers Squibb will have rights to opt-in to such genome editing tools for development of gene edited alpha-beta T cell therapies. For each new experimental medicine that Bristol Myers Squibb develops and commercializes using opted-into genome editing tools, Bristol Myers Squibb will pay Editas Medicine potential future milestone payments. Following the approval of any products resulting from the collaboration, Editas Medicine is also eligible to receive tiered royalties on net sales.

Posted In: BMY EDIT